Speculative Buy on Palisade Bio (PALI): Cheap Clinical-Stage Name with Asymmetric Upside
Palisade Bio is an underfollowed clinical-stage biotech developing oral therapies for post-operative and inflammatory gut disorders. With a market cap near $281M, ~ $28.8M in cash, a Canadian patent allowance for its PALI-2108 candidate, and Phase 1 expected progress, the risk/reward skews toward upside for catalytic readouts. Initiate a speculativ…